Post-ERCP Pancreatitis in Malpractice Litigation: A Guide for Defense Attorneys

Post-ERCP pancreatitis is the most common serious complication of ERCP (endoscopic retrograde cholangiopancreatography). It is also the most common basis for a post-ERCP pancreatitis malpractice claim. The two facts are related, and they are the reason defense counsel should understand this complication before the first expert report arrives.

Dr. Kalpit Devani, an interventional gastroenterologist in Greenville, South Carolina, provides defense-side expert witness consultation in gastroenterology and ERCP-related cases. This article explains how a practicing ERCP endoscopist reads a post-ERCP pancreatitis case. For the broader framework, see standard of care in ERCP.

The core problem for a plaintiff is simple. Pancreatitis occurs after ERCP even when the procedure is done correctly. Every published series shows this. So the question in these cases is rarely whether pancreatitis happened. It is whether anything the physician did or failed to do changed the odds, and whether that change caused this patient's outcome.

What Post-ERCP Pancreatitis Actually Is

The definition matters more than most attorneys expect. The accepted consensus definition of post-ERCP pancreatitis requires three things together: new or worsened abdominal pain, a pancreatic enzyme level (amylase or lipase) at least three times the upper limit of normal at roughly 24 hours after the procedure, and a hospital admission or a prolonged stay because of it.

A lab value alone does not meet the definition. Mild enzyme elevation after ERCP is common and often means nothing. Records sometimes label a patient with post-ERCP pancreatitis on the basis of one lipase result, without pain and without admission. When that happens, the diagnosis in the chart may not survive expert review.

Severity is graded by the length of the hospital stay and by whether the patient needed intervention, intensive care, or surgery. Most cases are mild. The severe cases, with necrosis or organ failure, are a small fraction, but they are the ones that generate claims.

The Baseline Risk of Pancreatitis After ERCP

Reported rates of pancreatitis after ERCP vary with the population studied. Unselected consecutive series often place the overall rate around three to four percent. Systematic reviews of randomized trials, which include more high-risk patients and capture complications more completely, report rates closer to ten percent. In patients with recognized risk factors, it is considerably higher still. Those risk factors include suspected sphincter of Oddi dysfunction, younger age, female sex, a prior episode of post-ERCP pancreatitis, difficult or prolonged cannulation, repeated injection of contrast into the pancreatic duct, and precut sphincterotomy.

Two things follow from this for the defense.

First, much of the risk is set by the patient and the anatomy before the scope goes in. A young woman with a normal bile duct diameter and unexplained pain carries a risk that no technique fully erases.

Second, a difficult cannulation is not evidence of poor technique. The papilla is not standardized. Some are easy. Some take many attempts by very experienced hands. The procedure note usually records how many attempts were made and whether the pancreatic duct was entered, and an expert reads those details in context rather than as a scorecard.

Common Claim Theories in Post-ERCP Pancreatitis Malpractice Cases

ERCP malpractice complaints involving pancreatitis tend to fall into a handful of theories. Knowing them in advance shortens the review.

The procedure should not have been done. The argument is that ERCP was performed without an adequate indication, often in a patient with abdominal pain and normal or borderline imaging. This is the strongest theory a plaintiff can bring, because if the indication was weak, every downstream risk becomes harder to defend. The record that matters here is the pre-procedure workup: imaging, labs, and the documented reasoning for choosing ERCP over MRCP or EUS.

Preventive measures were not used. Current guidelines from the major GI societies recommend rectal NSAIDs (usually indomethacin or diclofenac) around the time of ERCP for patients who do not have a contraindication, with aggressive intravenous fluids in many settings and a temporary pancreatic duct stent in selected higher-risk cases. A plaintiff will look for these in the chart. A reviewer looks for the same thing, but also for the reasons they may have been omitted: renal impairment, NSAID allergy, active bleeding, or a low-risk patient in an era or setting where routine use was not yet standard practice.

The technique caused the injury. This usually means repeated pancreatic duct cannulation, contrast injection into the pancreas, or the use of precut sphincterotomy. These are known risk factors, but they are also sometimes unavoidable in a difficult case. The question a reviewer asks is whether the approach was reasonable for what the endoscopist was facing, not whether a smoother procedure was imaginable in hindsight.

The complication was recognized too late. Pain after ERCP is expected in the recovery area. The claim is that the team dismissed persistent or escalating pain, sent the patient home, and delayed diagnosis. The timeline in the nursing notes, the discharge assessment, and the first contact after discharge decide this theory.

Consent was inadequate. Pancreatitis is a material risk of ERCP and belongs in the consent discussion. Most consent forms list it. The dispute is usually over whether the conversation happened, not whether the form was signed.

Causation: Where Post-ERCP Pancreatitis Malpractice Claims Are Usually Decided

Causation, not breach, is the hinge in most post-ERCP pancreatitis lawsuits.

Take the prophylaxis theory as an example. The landmark randomized trial of rectal indomethacin was performed in high-risk patients. Pancreatitis occurred in roughly nine percent of patients who received the drug and roughly seventeen percent of those who received placebo. The drug helped. It did not come close to eliminating the complication. So even where a reviewer concludes that indomethacin could have been given and was not, the plaintiff still has to show that this patient's pancreatitis more likely than not would have been prevented. The trial data cut against that.

The same logic applies to technique. A plaintiff expert may point to the number of cannulation attempts. The defense question is what the alternative was. Stopping the procedure and leaving a patient with cholangitis or an obstructed duct is not a safe option either. A practicing endoscopist can explain that tradeoff to a jury in plain terms. A physician who does not perform ERCP cannot.

What an ERCP Expert Witness Looks for in the Record

A defense expert reviewing one of these cases works through a predictable set of documents.

The indication note and the imaging that supported it. The consent form and any documented discussion. The procedure report, including the number and difficulty of cannulation attempts, whether the pancreatic duct was entered or injected, whether a wire was used, and whether a sphincterotomy or precut was performed. The medication record for rectal NSAIDs and the intravenous fluid volume. Any pancreatic duct stent placed. The recovery room assessment and discharge criteria. The first labs and imaging after symptoms appeared. And the management once pancreatitis was diagnosed.

Where a record is thin, it is usually thin in two places: the pre-procedure reasoning and the post-procedure timeline. Neither gap is fatal on its own, but both need to be understood early so the defense is not surprised at deposition.

Why the Choice of ERCP Expert Witness Matters

ERCP is a technical procedure with a steep learning curve. General gastroenterology board certification does not indicate that a physician performs ERCP at all, and many board-certified gastroenterologists do not. An expert who last performed ERCP in fellowship, or who performs a few a year, is exposed on cross-examination the moment the questioning turns to cannulation technique or the decision to precut.

A high-volume interventional endoscopist brings something a plaintiff often does not have: the ability to explain to a jury why a difficult papilla is difficult, why a reasonable endoscopist keeps going, and why pancreatitis remains a known and accepted risk of a properly performed procedure. More on how to evaluate that background is in choosing a gastroenterology expert witness for an advanced endoscopy case.

Dr. Devani performs complex ERCP at high volume, including procedures in surgically altered anatomy, and provides medico-legal expert witness review in gastroenterology and advanced endoscopy matters.

If you are defending a post-ERCP pancreatitis case and need a record reviewed, contact Dr. Devani for expert witness services.

Frequently Asked Questions

This article is for educational purposes only and does not constitute medical or legal advice.